Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

CARDIOME PHARMA CORP (COM)
Mes dernières consult.
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
1.84 1.8 1.8 1.8 1.81 Last
7610 3780 6960 2250 450 Volume
+3.37% -2.17% 0.00% 0.00% +0.56% Change
Financials ( CAD)
Sales 2017 33,5 M
EBIT 2017 -27,6 M
Net income 2017 -33,9 M
Debt 2017 -
Yield 2017 -
Sales 2018 49,4 M
EBIT 2018 -25,2 M
Net income 2018 -20,3 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 1,87x
Capi. / Sales2018 1,27x
Capitalization 62,7 M
More Financials
Company
Cardiome Pharma Corp. is a pharmaceutical company, which engages in the provision of development and commercialization of medical products.It focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.It offers the Brinavess and... 
Sector
Pharmaceuticals
Calendar
03/16Earnings Release
More about the company
Surperformance© ratings of Cardiome Pharma Corp
Trading Rating : Investor Rating :
More Ratings
Latest news on CARDIOME PHARMA CORP
02/08CARDIOME PHARMA : to Present at the Leerink Partners 7th Annual Global Healthcar..
PR
01/10CARDIOME PHARMA : to Participate in the Cantor Fitzgerald Antibiotics Summit
PR
2017CARDIOME PHARMA : Announces XYDALBA Treatment and Patient Experience Presentatio..
PU
2017CARDIOME PHARMA : Highlights Partner SteadyMed’s Agreement with the FDA on..
PU
2017CARDIOME PHARMA : Highlights Partner SteadyMed's Agreement With FDA On Pathway T..
PR
2017CARDIOME PHARMA : Announces Xydalba™ Treatment And Patient Experience Pres..
PR
2017CARDIOME PHARMA : to Present at the 29th Annual Piper Jaffray Healthcare Confere..
PR
2017CARDIOME PHARMA : Reports Third Quarter 2017 Financial Results
PR
2017CARDIOME PHARMA CORP : Cardiome Pharma Corp. to Host Earnings Call
AC
2017CARDIOME PHARMA : To Hold Third Quarter 2017 Financial Results Conference Call O..
PR
More news
Sector news : Biopharmaceuticals
09:15aAstraZeneca's immunotherapy drug wins key lung cancer approval
RE
08:37aASTRAZENECA : Cell Lung Cancer Treatment Imfinzi Gets FDA Approval
DJ
02/18NOVARTIS : CEO Steers Drug Maker Back to R&D
DJ
02/16S&P 500 caps off strongest week in five years
RE
02/16ASTRAZENECA : U.S. FDA approves AstraZeneca's immunotherapy for lung cancer
RE
More sector news : Biopharmaceuticals
Latest Tweets
02/13Canadian Exchanges Stock Scanner, OrganiGram Holdings, Concordia Internationa.. 
02/08Cardiome Pharma : to Present at the Leerink Partners 7th Annual Global Health.. 
02/03Zacks Investment Research Comments on Cardiome Pharma Corp’s FY2017 Earnings .. 
02/01Zacks Investment Research Sets Cardiome Pharma FY2017 Earnings Estimates at (.. 
01/24$CRME - Cardiome Pharma #CRME Receiving Somewhat Positive News Coverage, Anal.. 
More tweets
Qtime:18
News from SeekingAlpha
02/09Key healthcare events next week (continued) 
2017YOUR DAILY PHARMA SCOOP : Ultragenyx Sells Voucher, Regeneron Announces Collabor.. 
2017Cardiome Pharma's (CRME) CEO William Hunter on Q3 2017 Results - Earnings Cal.. 
2017Cardiome Pharma misses by $0.02, misses on revenue 
2017Notable earnings after Tuesday?s close 
Chart CARDIOME PHARMA CORP
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Technical analysis trends CARDIOME PHARMA CORP
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 8,91  CAD
Spread / Average Target 392%
EPS Revisions
Managers
NameTitle
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Justin A. Renz Chief Financial Officer
Richard M. Glickman Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CARDIOME PHARMA CORP-11.71%50
BIOGEN-7.06%63 312
CSL LIMITED7.22%54 288
ALEXION PHARMACEUTICALS3.02%27 311
GRIFOLS SA-4.40%18 471
BIOMARIN PHARMACEUTICAL-5.19%14 847